Elon Musk’s pioneering neurotechnology firm Neuralink—best known for developing brain-computer interfaces that promise to revolutionize medicine and human-machine interaction—has recently identified itself as a ‘Small Disadvantaged Business’ (SDB) in filings with the U.S. federal government. This move, revealed in a Small Business Administration (SBA) profile updated in April 2025, has drawn sharp attention throughout the tech, policy, and investment worlds.

Neuralink’s self-certification as an SDB enables it to compete for certain government contracts earmarked specifically for companies that are majority owned and controlled by socially and economically disadvantaged individuals. Yet, given Musk’s position as the world’s richest man—estimated net worth exceeding $412 billion according to Forbes—and Neuralink’s backing by powerful Silicon Valley investors, critics and watchdogs are questioning whether the company fits not just the letter, but the spirit of these programs.

Background: What is a Small Disadvantaged Business?

Under SBA guidelines, SDB status is awarded to entities that are at least 51% owned and controlled by individuals deemed to be socially and economically disadvantaged, as defined by federal regulations. The SDB designation is meant to redress historical inequities by granting such businesses access to 10% of the roughly $650 billion in U.S. federal contracts awarded annually.

The SBA relies on a self-certification process—companies attest to their status when registering through sam.gov. The SBA does not automatically vet each claim, although the agency can review and, if necessary, revoke certifications after further investigation. Misrepresentation may result in steep penalties: in 2021, several firms paid multi-million-dollar fines for false SDB filings.^[1]

Neuralink: High Profile, Secretive Structure

Neuralink, founded in 2016 by Elon Musk and a team of leading neuroscientists and engineers, is developing implantable brain chips aimed at restoring mobility to paralyzed patients and enabling seamless communication between the brain and digital devices. In 2023, the company generated global headlines when a paralyzed man, Noland Arbaugh, successfully used a Neuralink chip to move a computer cursor by thought alone.^[2]

The company employs between 200 and 500 staff, according to its LinkedIn page, and is backed by prominent investors such as Peter Thiel’s Founders Fund. In 2024, Neuralink completed a $650 million funding round,^[3] cementing its place among the world’s highest-valued private biotech startups.

Despite these resources, Neuralink’s SDB self-certification claimed majority ownership and control by socially and economically disadvantaged individuals. The company, however, has not publicly disclosed its full list of executives and shareholders, and declined to respond to multiple media inquiries about the specifics of its claim. SBA records show the company’s profile was updated as recently as April 2025.

Government Scrutiny and Ethical Concerns

This surprising self-designation has drawn scrutiny from legal experts and lawmakers. “Given Mr. Musk’s global wealth and Neuralink’s high-profile backing, it would be deeply concerning if the company incorrectly claimed disadvantaged status and benefited from federal preferences,” said a Washington D.C.-based procurement attorney familiar with SBA programs. The Justice Department and SBA have not confirmed any formal investigation, but watchdog groups have called for closer review.

Industry leaders warn that any misuse of SDB status undermines the goals of programs designed to empower truly marginalized entrepreneurs in technology and medicine. “The heart of small business programs is to serve genuinely disadvantaged innovators—not global tech giants,” noted Candace Jones, executive director at the National Association for Economic Inclusion. Such programs have come under increased scrutiny after multiple high-profile abuses in the past decade.

Neuralink’s Progress and Controversies

Beyond legal controversy, Neuralink is pushing forward rapidly on the technical front. In 2024, the first successful live implant in a human patient marked a new milestone for brain-computer interfaces. Test subject Noland Arbaugh, aged 30, shared his experience with the BBC, describing how he could control a cursor and play computer games using only his thoughts. Neuralink claims at least three individuals have now received the device, and plans to expand trials to another 20–30 patients by the end of 2025.^[4]

Musk has remained a vocal proponent of merging human cognition with artificial intelligence, but Neuralink’s fast pace has fueled ethical debates—especially around patient consent, long-term neurological impacts, and data security. Medical associations, including the American Medical Association (AMA), are urging regulatory agencies to proceed with caution and ensure clinical transparency.^[5]

The Musk–Trump Connection and Political Repercussions

Adding another layer of intrigue is Elon Musk’s former close relationship with President Donald Trump. While Musk was recognized as a “special government employee” in the Trump administration, pushback against government red tape and restructuring of federal agencies were key priorities. Neuralink’s SBA filing period overlaps with Musk’s government role, according to reporting by Muskwatch and government records, further raising questions about political influence in federal procurement and oversight.

Public fallout between Musk and Trump in mid-2025, coupled with Musk’s recent outspoken statements about tech industry ethics and governance, may place Neuralink’s business decisions under even brighter spotlight as the 2024 U.S. general election cycle intensifies debates about technology’s role in government and society.

What Comes Next for Neuralink?

While Neuralink continues to break new scientific ground, the company now faces calls for greater transparency regarding its corporate structure and use of government certifications. Regulatory scrutiny could grow as U.S. authorities re-emphasize oversight of federal funds and contracting programs.

Meanwhile, the stakes for brain-computer technology remain immense. Recent forecasts by Statista project the global brain-computer interface market will surpass $3.3 billion by 2030, growing at a double-digit annual rate. As Neuralink prepares for further human trials, its trajectory will be closely watched—not only for technological breakthroughs but also as a test for ethical leadership and responsible innovation in Silicon Valley.